(Approval lapsed) Dobutamine 12.5mg/mL (250mg/20mL) concentrate for solution for infusion (Hameln)
Section 19A approved medicine
(Approval lapsed) Dobutamine 12.5mg/mL (250mg/20mL) concentrate for solution for infusion (Hameln)
Section 19A approval holder
ORSPEC Pharma Pty Ltd ABN 15 634 980 417
Phone
02 4339 4239
Approved until
Status
Expired
Medicines in short supply/unavailable
DBL DOBUTAMINE 250mg/20mL (as hydrochloride) injection vial - ARTG 46451
Indication(s)
Dobutamine Hydrochloride Injection is indicated in adults who require short-term treatment of cardiac failure secondary to acute myocardial infarction, or cardiac surgery.
Images
